Welcome to our dedicated page for Alumis SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. reported a stock option grant to Chief Scientific Officer David M. Goldstein. On January 26, 2026, he received an option to buy 216,675 shares of common stock at an exercise price of $26.31 per share, held as a direct derivative position.
According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continued service under the company’s 2024 Equity Incentive Plan.
Alumis Inc. director Srinivas Akkaraju reported an indirect purchase of Alumis common stock tied to investment entities he is associated with. On January 9, 2026, Samsara Opportunity Fund, L.P. acquired 588,235 shares of Alumis common stock at $17 per share, reported with transaction code "P." After this trade, Samsara Opportunity Fund, L.P. was shown as holding 1,853,488 shares of Alumis indirectly for the reporting person.
The filing also notes an additional 4,491,731 shares of Alumis common stock held indirectly through Samsara BioCapital, L.P. Akkaraju is a managing member or has voting and investment power in the related general partners and may be deemed to beneficially own these holdings, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
Alumis Inc. received an updated ownership report from investment entities affiliated with Srinivas Akkaraju. Samsara BioCapital, L.P. reports beneficial ownership of 4,491,731 shares of Alumis common stock, representing 3.8% of the class, while Samsara Opportunity Fund, L.P. reports 1,853,488 shares, or 1.6%. Dr. Akkaraju is reported to beneficially own 6,345,219 shares in total, equal to 5.4% of Alumis' voting common stock.
The filing details a series of open-market purchases by Samsara Opportunity Fund between late November and early December 2025 at prices generally between about $7.31 and $11.005 per share, plus a purchase of 588,235 shares at $17.00 per share in Alumis' January 2026 public offering. The aggregate purchase price for these securities from November 26, 2025 through January 9, 2026 was $15,209,937.96.
Foresite Capital entities and James B. Tananbaum have updated their disclosure of ownership in Alumis Inc. common stock in this Amendment No. 3 to Schedule 13D. The filing shows that Tananbaum is deemed to beneficially own 16,189,804 shares, or 14.1% of Alumis’s common stock, through a network of Foresite funds and affiliated LLCs.
The amendment reflects dilution from Alumis issuing additional shares and new purchases, including participation in the July 2024 IPO at $16.00 per share, multiple open-market purchases in 2025, and a follow-on offering on January 8, 2026 where Fund V and Opportunity Fund V bought shares at $17.00 per share. The reporting persons state they hold the position for investment purposes and may buy more, hold, sell, or distribute shares depending on market conditions and their assessment of Alumis’s business.
Alumis Inc. reported insider activity by investment entities affiliated with Foresite Labs and related funds. On 01/08/2026, these entities executed open‑market purchases of Alumis common stock, including 117,647 shares at $17 per share and a separate purchase of 294,117 shares at $17 per share. After these trades, the reporting structures show indirect beneficial ownership positions such as 5,702,536 shares and 2,908,332 shares in specific funds, along with additional indirect holdings in other affiliated vehicles. The reporting persons, Foresite Labs, LLC and Foresite Labs Affiliates 2021, LLC, are identified as more than 10% owners, and the footnotes explain that the shares are held through various Foresite Capital and Foresite Labs entities with beneficial ownership disclaimed except for each party’s pecuniary interest.
Alumis Inc. (ALMS) received a Form 4 filing from several Foresite Capital and Foresite Labs investment entities that are 10% owners, reporting indirect ownership of Alumis common stock.
On January 8, 2026, Foresite Capital Fund V, L.P. purchased 117,647 Alumis common shares at $17 per share, bringing its indirectly reported holdings to 5,702,536 shares. On the same date, Foresite Capital Opportunity Fund V, L.P. purchased 294,117 shares at $17 per share, with indirectly reported holdings of 2,908,332 shares.
The filing also lists additional indirect common stock holdings: Foresite Capital Fund VI, L.P. with 4,247,670 shares, Labs Co-Invest V, LLC with 194,459 shares, Foresite Labs Fund I, L.P. with 1,960,337 shares, and Foresite Labs Affiliates 2021, LLC with 1,176,470 shares. The reporting entities note that they may be deemed to have voting and dispositive power through their general partners or managing members and each disclaims group status and beneficial ownership beyond its pecuniary interest.
Alumis Inc. director and 10% owner James B. Tananbaum filed a Form 4 reporting indirect ownership changes through investment entities. On January 8, 2026, entities associated with him purchased 117,647 and 294,117 shares of Alumis common stock at $17 per share, reported as indirect acquisitions. The filing also lists sizable indirect holdings in Alumis common stock by multiple Foresite Capital and Foresite Labs funds and LLCs, including Foresite Capital Fund V, Foresite Capital Opportunity Fund V, Foresite Capital Fund VI, Labs Co-Invest V, Foresite Labs Fund I and Foresite Labs Affiliates 2021. The footnotes state that these entities hold the shares of record and that Tananbaum may be deemed to share or have voting and dispositive power, while he disclaims beneficial ownership except for his pecuniary interest.
Alumis Inc. reported that its preliminary unaudited cash, cash equivalents and marketable securities totaled approximately $308.6 million as of December 31, 2025. This figure is management’s estimate and has not been audited, reviewed or examined by PricewaterhouseCoopers LLP and may change once the quarter- and year-end closing process is completed.
The company also entered into an underwriting agreement for a public offering of 17,650,000 shares of its common stock at $17.00 per share$345.1 million before underwriting discounts, commissions and expenses. The offering is expected to close on January 9, 2026, and the underwriters’ 30‑day option to purchase up to 2,647,500 additional shares was exercised in full on January 8, 2026.
Alumis Inc. is offering 17,650,000 shares of its common stock at $17.00 per share, for gross proceeds of $300,050,000 and estimated net proceeds of about $281.5 million. The company has also granted underwriters a 30‑day option to buy up to 2,647,500 additional shares. Alumis plans to use the cash, together with existing funds, to support a planned NDA filing and launch preparations for its TYK2 inhibitor envu in plaque psoriasis, advance envu and other pipeline programs, and for general corporate purposes.
The company recently reported positive Phase 3 ONWARD1 and ONWARD2 results for envu in moderate‑to‑severe plaque psoriasis, with 74% of patients achieving PASI 75 and 59% achieving sPGA 0/1 at Week 16 on average across both trials, and strong PASI 90/100 responses by Week 24. Based on preliminary estimates, Alumis had approximately $308.6 million in cash, cash equivalents and marketable securities as of December 31, 2025, but its disclosures note substantial doubt about its ability to continue as a going concern without significant additional capital. After this offering, Alumis expects to fund operations into the fourth quarter of 2027, though investors will face immediate and substantial dilution.
Alumis Inc. filed a report describing new communications about its oral psoriasis therapy envudeucitinib. The company issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program” and furnished it as an exhibit. Alumis also posted an updated corporate presentation for investors and attached it as a separate exhibit.
The report notes that these materials contain forward-looking statements, including Alumis’s plans to submit a new drug application in the second half of 2026 and the potential for envudeucitinib to address IL-23/IL-17–driven diseases and those driven by Type I interferon. Alumis cautions that regulatory decisions, clinical trial outcomes, funding, and intellectual property protection could cause actual results to differ from these expectations.
Alumis Inc. filed a report describing new communications about its oral psoriasis therapy envudeucitinib. The company issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program” and furnished it as an exhibit. Alumis also posted an updated corporate presentation for investors and attached it as a separate exhibit.
The report notes that these materials contain forward-looking statements, including Alumis’s plans to submit a new drug application in the second half of 2026 and the potential for envudeucitinib to address IL-23/IL-17–driven diseases and those driven by Type I interferon. Alumis cautions that regulatory decisions, clinical trial outcomes, funding, and intellectual property protection could cause actual results to differ from these expectations.